A new mechanism of action of thienopyridine antiplatelet drugs - A role for gastric nitrosthiol metabolism?

Atherosclerosis

Volumn 237, Issue 1, 2014, Pages 369-373

  Anderson, R A ^a   Bundhoo, S ^a   James, P E ^b  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Clopidogrel; Nitrosothiols; Platelet inhibition; Platelets

Indexed keywords

CLOPIDOGREL; DRUG METABOLITE; NITRIC OXIDE; PRASUGREL; S NITROSOTHIOL; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE; ANTITHROMBOCYTIC AGENT; NITRIC ACID DERIVATIVE; NITROGEN; OXYGEN; P2RY12 PROTEIN, HUMAN; PURINERGIC P2Y12 RECEPTOR; PYRIDINE DERIVATIVE; THIOL DERIVATIVE;

ARTICLE; BIOTRANSFORMATION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; IN VITRO STUDY; STOMACH ACID; SYNTHESIS; ACUTE CORONARY SYNDROME; ANALOGS AND DERIVATIVES; BIOLOGICAL MODEL; CHEMISTRY; DRUG EFFECTS; HUMAN; METABOLISM; PH; STOMACH; THROMBOCYTE;

ACUTE CORONARY SYNDROME; BLOOD PLATELETS; HUMANS; HYDROGEN-ION CONCENTRATION; MODELS, BIOLOGICAL; NITRATES; NITRIC OXIDE; NITROGEN; OXYGEN; PLATELET AGGREGATION INHIBITORS; PYRIDINES; RECEPTORS, PURINERGIC P2Y12; S-NITROSOTHIOLS; STOMACH; SULFHYDRYL COMPOUNDS; TICLOPIDINE;

EID: 84908053435     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.08.045     Document Type: Article

References (39)

1. Arandomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996, 348:1329-1339.
2. Bhatt D.L., Fox K.A., Hacke W., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. NEngl J Med 2006, 354:1706-1717.
3. Chen Z.M., Jiang L.X., Chen Y.P., et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005, 366:1607-1621.
4. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., Fox K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. NEngl J Med 2001, 345:494-502.
5. Sabatine M.S., Cannon C.P., Gibson C.M., et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. NEngl J Med 2005, 352:1179-1189.
6. Mehta S.R., Yusuf S., Peters R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001, 358:527-533.
7. Geisler T., Langer H., Wydymus M., et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006, 27:2420-2425.
8. Bonello L., Tantry U.S., Marcucci R., et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. JAm Coll Cardiol 2010, 56:919-933.
9. Wurtz M., Grove E.L. Interindividual variability in the efficacy of oral antiplatelet drugs: definitions, mechanisms and clinical importance. Curr Pharm Des 2012, 18(33):5344-5361.
10. Hulot J.S., Collet J.P., Silvain J., et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. JAm Coll Cardiol 2010, 56:134-143.
11. Hulot J.S., Collet J.P., Montalescot G. Thienopyridine-associated drug-drug interactions: pharmacologic mechanisms and clinical relevance. Curr Cardiol Rep 2011, 13:451-458.
12. Frelinger A.L., Bhatt D.L., Lee R.D., et al. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. JAm Coll Cardiol 2013, 61:872-879.
13. Collet J.P., Cuisset T., Range G., et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. NEngl J Med 2012, 10.1056/NEJMoa1209979.
14. Savi P., Zachayus J.L., Delesque-Touchard N., et al. The active metabolite of clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc Natl Acad Sci U S A 2006, 103:11069-11074.
15. Ding Z., Kim S., Dorsam R.T., Jin J., Kunapuli S.P. Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. Blood 2003, 101:3908-3914.
16. Lander H.M. Cellular activation mediated by nitric oxide. Methods 1996, 10:15-20.
17. Keese M.A., Bose M., Mulsch A., Schirmer R.H., Becker K. Dinitrosyl-dithiol-iron complexes, nitric oxide (NO) carriers invivo, as potent inhibitors of human glutathione reductase and glutathione-S-transferase. Biochem Pharmacol 1997, 54:1307-1313.
18. McKnight G.M., Smith L.M., Drummond R.S., Duncan C.W., Golden M., Benjamin N. Chemical synthesis of nitric oxide in the stomach from dietary nitrate in humans. Gut 1997, 40:211-214.
19. Bundhoo S.S., Anderson R.A., Sagan E., et al. Direct formation of thienopyridine-derived nitrosothiols - just add nitrite!. Eur J Pharmacol 2011, 670:534-540.
20. Anderson R.A., Bundhoo S., Sagan E., James P.E. Acute clopidogrel loading doses result in favourable changes in nitric oxide (NO) metabolism in patients with stable coronary artery disease undergoing percutaneous coronary intervention. Thromb Haemost 2014, 111(2):373-374.
21. Bundhoo S.S., Anderson R.A., Sagan E., Dada J., Harris R., Halcox J.P., et al. Direct vasoactive properties of thienopyridine-derived nitrosothiols. JCardiovasc Pharmacol 2011, 58(5):550-558.
22. Webb A.J., Patel N., Loukogeorgakis S., et al. Acute blood pressure lowering, vasoprotective, and antiplatelet properties of dietary nitrate via bioconversion to nitrite. Hypertension 2008, 51:784-790.
23. Heitzer T., Rudolph V., Schwedhelm E., et al. Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects. Arterioscler Thromb Vasc Biol 2006, 26:1648-1652.
24. Jakubowski A., Chlopicki S., Olszanecki R., et al. Endothelial action of thienopyridines and thienopyrimidinones in the isolated guinea pig heart. Prostaglandins Leukot Essent Fatty Acids 2005, 72:139-145.
25. Warnholtz A., Ostad M.A., Velich N., et al. Asingle loading dose of clopidogrel causes dose-dependent improvement of endothelial dysfunction in patients with stable coronary artery disease: results of a double-blind, randomized study. Atherosclerosis 2008, 196:689-695.
26. Andrews N.P., Husain M., Dakak N., Quyyumi A.A. Platelet inhibitory effect of nitric oxide in the human coronary circulation: impact of endothelial dysfunction. JAm Coll Cardiol 2001, 37(2):510-516.
27. Gordge M.P., Xiao F. S-Nitrosothiols as selective antithrombotic agents - possible mechanisms. Br J Pharmacol 2010, 159:1572-1580.
28. Pigazzi A., Heydrick S., Folli F., Benoit S., Michelson A., Loscalzo J. Nitric oxide inhibits thrombin receptor-activating peptide-induced phosphoinositide 3-kinase activity in human platelets. JBiol Chem 1999, 274:14368-14375.
29. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res 2001, 88:756-762.
30. Sambu N., Warner T., Curzen N. Clopidogrel withdrawal: is there a "rebound" phenomenon?. Thromb Haemost 2011, 105:211-220.
31. Gurbel P.A., Lau W.C., Tantry U.S. Omeprazole: a possible new candidate influencing the antiplatelet effect of clopidogrel. JAm Coll Cardiol 2008, 51:261-263.
32. Gilard M., Arnaud B., Cornily J.C., et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. JAm Coll Cardiol 2008, 51:256-260.
33. Li X.Q., Andersson T.B., Ahlstrom M., Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004, 32:821-827.
34. Fock K.M., Ang T.L., Bee L.C., Lee E.J. Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes?. Clin Pharmacokinet 2008, 47:1-6.
35. Cuisset T., Frere C., Quilici J., et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors and Clopidogrel Association) prospective randomized study. JAm Coll Cardiol 2009, 54:1149-1153.
36. Schafer A., Flierl U., Pfortsch S., Seydelmann N., Micka J., Bauersachs J. The H(2)-receptor antagonist ranitidine interferes with clopidogrel-mediated P2Y(12) inhibition in platelets. Pharmacol Res 2010, 62:352-356.
37. Ghebremariam Y.T., LePendu P., Lee J.C., Erlanson D.A., Slaviero A., Shah N.H., et al. Unexpected effect of proton pump inhibitors - elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation 2013, 128:845-853.
38. Bhatt D.L., Cryer B.L., Contant C.F., Cohen M., Lanas A., Schnitzer T.J., et al. NEngl J Med 2010, 363(20):1909-1917.
39. D1 Aradi, Kuliczkowski W., Atar D., Serebruany V.L. Inter-patient variability and impact of proton pump inhibitors on platelet reactivity after prasugrel. Thromb Haemost 2012 Feb, 107(2):338-345. 10.1160/TH11-09-0622.